CD ComputaBio Announces PD-L1 Targeting Service for Anticancer Drug Research

CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of PD-L1 targeting service for cancer research.

Over the past decade, immunotherapy has become one of the mainstays of cancer treatment, thanks in large part to monoclonal antibodies targeting the immune checkpoint protein PD-1 or its major ligand PD-L1 (mAbs).

Due to abnormal immune surveillance mediated by immune checkpoints, tumor cells develop immune escape and subsequently acquire the ability to proliferate indefinitely. Among such immune checkpoints, PD-1/PD-L1 has been recognized as an anticancer drug target for many years. To date, a variety of monoclonal antibodies targeting the PD-1/PD-L1 signaling pathway have been developed, resulting in encouraging achievements in cancer therapy. Current preclinical studies have shown that small molecule compounds have better ability to inhibit tumor growth and migration than antibodies, and have good biosafety.

PD-1/PD-L1 activates human T cells to play an anti-tumor effect by releasing the inhibitory effect of tumor on cellular immunity. Its effectiveness is mainly reflected in malignant solid tumors, and it has been proved effective in a variety of malignant solid tumors. However, the overall effective rate in the non-selected population is only about 20%, and the effective rate of some solid tumors such as Hodgkin lymphoma is very high. In some tumors, such as gastric cancer and pancreatic cancer, it has not been proven effective. In other well-defined solid tumors such as lung cancer and colorectal cancer, its efficacy is related to tumor PD-L1 expression or other efficacy predictive markers.

In terms of safety, because the mechanism of PD-1/PD-L1 is to activate the body's cellular immunity to tumors, its overall safety is better than traditional cytotoxic drugs, and even better than some small molecule targeted drugs.

CD ComputaBio’s PD-L1 targeting solutions support scientists all benefit from the following services:

1. PD-L 1 Target Analysis
2. Build Pharmacophore
3. Virtual Screening
4. Druggability Assessment
5. Protein and Candidate Interaction Prediction

“Our technology enables structure-based evaluation studies of PD-L 1, providing additional readout on druggability when no or few drug-like compounds are known, allowing investigators to successfully predict allosteric for modulation Site, surface for PPI, and mAb binding. Our technology can also evaluate the druggability parameters of the screened candidates, such as log P, lipid-water partition coefficient, molecular weight, etc.” said the product manager of CD ComputaBio.

“The services provided by CD ComputaBio are based on cutting-edge computational platform and technology in this field with accuracy and sensitivity. We can provide a fast turnaround, clear concise written reports, and custom service to help customers resolve their technical challenges,” he added.

About CD ComputaBio

With years of experience, CD ComputaBio can provide customers with professional computational biology services. Utilizing rich experience and powerful technology in computational science, the company can provide customers with many computational biology analysis services such as molecular dynamics simulation, drug design, virtual screening, quantum chemical calculations, etc.

Media Contact

Company Name: CD ComputaBio

Contact Person: Vivian Smith

Phone: 1-631-371-4691

Country: United States

Website: https://www.computabio.com